MME and hydrops fetalis: Large analysis of over 300 000 HF patients points out that compared with RAAS inhibitors, ARB valsartan combined with the neprilysin inhibitor sacubitril is more beneficial to patients with HF and also significantly reduce the rates of GFR decline in CHF, further moderate end-stage kidney disease [13, 72–74].